Literature DB >> 25522221

Oral steroid therapy as an adjuvant treatment for severe epidemic keratoconjunctivitis in patients younger than 3 years.

Sun Young Kim1, Young Kwon Chung, Young-Chun Lee, Su-Young Kim.   

Abstract

PURPOSE: To evaluate the therapeutic effect of oral steroids given to patients younger than 3 years with epidemic keratoconjunctivitis (EKC) accompanied by severe eyelid edema and inflammatory ptosis, in whom eye drops were not feasible.
METHODS: This study included 9 patients treated for EKC in local clinics whose condition failed to improve due to severe eyelid swelling together with difficulties in application of eye drops and pseudomembrane removal. We analyzed the extent of eyelid swelling, corneal damage, follicles, chemosis, and pseudomembrane formation in these patients before and after oral corticosteroid therapy in collaboration with the pediatrics department.
RESULTS: After a mean of 1.8 ± 0.7 days of oral steroid treatment, eyelid edema, corneal damage, conjunctival injection, follicles, and chemosis improved in all patients.
CONCLUSIONS: Oral steroids are an effective adjuvant treatment for EKC in patients younger than 3 years in whom eye drops could not be administered frequently due to severe eyelid edema.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25522221     DOI: 10.1097/ICO.0000000000000332

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  3 in total

1.  Chemosis as complication in transconjunctival approach for orbital trauma.

Authors:  Sergio Olate; Celso Palmieri; Márcio de Moraes
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2017-02-20

2.  Persistent Symblepharon in an Infant Following Epidemic Keratoconjunctivitis.

Authors:  Sezen Akkaya; Yelda Buyru Ozkurt
Journal:  Med Hypothesis Discov Innov Ophthalmol       Date:  2016

3.  A 8-year retrospective clinical analysis of 272 patients of epidemic Keratoconjunctivitis in Beijing, China.

Authors:  Wenbo Hou; Xuguang Sun; Jun Feng; Yang Zhang; Zhiqun Wang
Journal:  BMC Ophthalmol       Date:  2019-12-19       Impact factor: 2.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.